DERWENT-ACC-NO: 1999-010294
DERWENT-WEEK: 200102

TITLE: Pentaerythritol derivatives - are useful as vasodilating agents, endothelium-protective agents or platelet aggregation-inhibiting agents

INVENTOR: BROSIG, H; HESS, U ; KOENIG, G ; WINDECK, A

PATENT-ASSIGNEE: ISIS PHARMA GMBH[ISISN]

PRIORITY-DATA: 1997DE-1025340 (June 11, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
SK 9901695 A3	November 7, 2000	N/A	000	C07D 271/07
ZA 9805064 A	October 28, 1998	E	042	C07C 000/00
DE 19826781 A1	December 17, 1998	N/A	000	C07D 271/07
WO 9856759 A2	December 17, 1998	G	000	C07C 271/00
AU 9885321 A	December 30, 1998	N/A	000	C07C 271/00
NO 9906128 A	December 10, 1999	N/A	000	C07C 271/00
EP 988282 A2	March 29, 2000	G	000	C07C 271/00
DE 19880813 T	May 31, 2000	N/A	000	C07C 271/00
CN 1266429 A	September 13, 2000	N/A	000	C07D 271/07

DESIGNATED-STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI G
B GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW A L AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI

APPLICATION-DATA:

PUB-NO	APPL-DESCRIPTOR	APPL-NO	APPL-DATE
SK 9901695A3	N/A	1998WO-DE01635	June 11, 1998
SK 9901695A3	N/A	1999SK-0001695	June 11, 1998
ZA 9805064A	N/A	1998ZA-0005064	June 11, 1998
DE 19826781A1	N/A	1998DE-1026781	June 11, 1998
WO 9856759A2	N/A	1998WO-DE01635	June 11, 1998
AU 9885321A	N/A	1998AU-0085321	June 11, 1998
AU 9885321A	Based on	WO 9856759	N/A
NO 9906128A	N/A	1998WO-DE01635	June 11, 1998
NO 9906128A	N/A	1999NO-0006128	December 10, 1999
EP 988282A2	N/A	1998EP-0936180	June 11, 1998
EP 988282A2	N/A	1998WO-DE01635	June 11, 1998
EP 988282A2	Based on	WO 9856759	N/A
DE 19880813T	N/A	1998DE-1080813	June 11, 1998

DE 19880813T	N/A	1998WO-DE01635	June 11, 1998
DE 19880813T	Based on	WO 9856759	N/A
CN 1266429A	N/A	1998CN-0808056	June 11, 1998

INT-CL_(IPC): A61K031/41; C06B000/00 ; C07B000/00 ; C07C000/00 ; C07C203/04 ; C07C229/22 ; C07C271/00 ; C07D271/07 ; C07F000/00

ABSTRACTED-PUB-NO: ZA 9805064A

BASIC-ABSTRACT: Pentaerythritol derivatives of formula (I), (III), (VI), (VII), (VIII) and (XV) and their salts are new: (O2NOCH2)mC(CH2OH)n(CH2COR1)o(COR1)p (I) (O2NOCH2)mC(CH2OH)n(CH2COR3)o(COR3)p (III) (O2NOCH2)mC(CH2OH)n(CH2COR5)o(COR5)p (VI) (HOCH2)q(O2NOCH2)rC(CH2OR6) s (VII) (O2NOCH2)mC(CH2OH)n(CH2COR7)o(COR7)p (VIII) (HOCH2)q(O2NOCH2)rC(CH2OR14)s (XV) R1 = a group of formula (II); R3 = a group of formula (IV); R5 = (2-carboxyphenyl)oxy or (2-alkoxycarbonylphenyl)oxy; R6 = salicyloyl or acetylsalicyloyl; R7 = a group of formula (IX); R14 = acyl radical of a compound of formula (X), (XI), (XII), (XIII) or (XIV) (sic); R2 = 1-20C alkyl, especially Me, Et, n-Pr, i-Pr, n-butyl, n-pentyl, n-hexyl, n-octyl, benzyl, cyclohexylmethyl, 4-chlorobenzyl, 4-nitrobenzyl, 2-phenylethyl, 3-phenylpropyl, 3-cyclohexylpropyl, 3-phthalimidylpropyl, 1-naphthylmethyl, cinnamyl, 5-ethoxycarbonylbutyl, 3-aminopropyl, -(CH2)3CH(NHCOCH3)COOH, -(CH2)3CH(NHCOCH3)COOCH3 or 1,6-hexane-bis; R8, R9 = 1-6C alkyl or R8+R9 = 1-6C alkylene; R10 = OH, NHR8R9, 1-6C alkoxy, (2-carboxyphenyl)oxy, (2-alkoxycarbonylphenyl)oxy, (1-carboxymethyl-2-dialkylamino)ethoxy, (1-carboxymethyl-2-trialkylammoni- um)ethoxy, (1-alkoxycarbonylmethyl-2-dialkylamino)ethoxy or (1-alkoxycarbonylmethyl-2-trialkylammonium)ethoxy; m, p, r, s at least 1; m+n+o+p = 4; q+r+s = 4. Also claimed are compounds of formula (V), (X), (XI) and (XIV) and their salts. R4 = H, 1-6C alkanoyl, salicyloyl or acetylsalicyloyl; R11 = NO2 and for (XV) H, 1-6C alkanoyl, salicyloyl, acetylsalicyloyl or -CO-CH2CH(OH)-CH2-NR8R9; R12 = 1-6C alkyl, especially Me, Et or n-Pr; R13 = H or 1-6C alkyl; X = an anion or absent if COR10 is capable of forming an inner salt.

USE - (I), (III), (V) and (VI) are useful as vasodilating agents, endothelium-protective agents or platelet aggregation-inhibiting agents and can be used in combination with other agents (especially ACE inhibitors, antiatherosclerotics, antihypertensives, beta -blockers, cholesterol-lowering agents, diuretics, calcium antagonists, coronary dilators, lipid-lowering agents, peripheral vasodilators, phosphodiesterases or platelet aggregation inhibitors) for the treatment of cardiovascular or vessel diseases.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS:
PENTAERYTHRITOL DERIVATIVE USEFUL VASODILATING AGENT ENDOTHELIUM PROTECT AGENT
PLATELET AGGREGATE INHIBIT AGENT

DERWENT-CLASS: B03 B05

CPI-CODES: B07-E04; B10-A05; B14-F01B; B14-F02D; B14-F04;

CHEMICAL-CODES:
Chemical Indexing M2 *01*
Fragmentation Code
D014 D019 D611 D699 F013 F014 F015 F019 F021 F029
F630 F699 G010 G011 G013 G019 G020 G029 G030 G039
G100 G111 G112 G221 G299 G563 G599 H100 H101 H103
H181 H182 H183 H201 H202 H211 H212 H213 H341 H342
H401 H441 H481 H602 H608 H641 H642 J0 J012 J013
J014 J131 J132 J171 J172 J221 J222 J231 J232 J241
J242 J271 J272 J273 J321 J322 J371 J372 J521 J522
J523 K0 K7 K710 L355 L399 L722 L724 L910 L999
M210 M211 M212 M213 M214 M215 M216 M220 M221 M222
M223 M224 M225 M226 M231 M232 M233 M262 M272 M273
M280 M281 M282 M283 M311 M312 M313 M314 M321 M322
M323 M332 M334 M342 M343 M344 M349 M373 M381 M383
M391 M392 M393 M412 M413 M414 M416 M510 M511 M512
M520 M521 M522 M523 M530 M531 M532 M533 M540 M541
M542 M620 M630 M640 M650 M710 M903 M904 P520 P522
P528 P813
Ring Index
00083
Markush Compounds
199901-BN001-N 199901-BN001-T

SECONDARY-ACC-NO:
CPI Secondary Accession Numbers: C1999-003509

STIC-ILL 348,081 Adons - No hits

From: Hui, San-Ming
Sent: Friday, May 25, 2001 4:57 PM
To: STIC-ILL
Subject: Document request

Please get me the following 2 articles. thanks

Room: 2A12; MailBox: 2B19

ACCESSION NUMBER: 1999:169015 TOXLINE
DOCUMENT NUMBER: IPA-99-1179444
TITLE: Cardiovascular risk reduction through promotion of the ABCS in ischemic heart disease in a veteran population.
COMMENT: Abstract of Meeting Presentation
AUTHOR: Liao M M; Huynh K C; Gray D R; Hagar J M
CORPORATE SOURCE: Veterans Affairs Medical Center (119), 5901 East Seventh Street, Long Beach, CA 90822, USA Internet:. mliao2l@hotmai l.com
SOURCE: ASHP Midyear Clinical Meeting, (1999). Vol. 34, Dec PP-150D (REF).
FILE SEGMENT: IPA
LANGUAGE: English
OTHER SOURCE: IPA 36-1179444
ENTRY MONTH: 199911
AB IPA COPYRIGHT: ASHP The risk for recurrent cardiovascular event can be reduced through pharmacotherapy and lifestyle modifications described by the ABCS: aspirin; angiotensin converting enzyme inhibitors; beta -blockers; cholesterol lowering agents; smoking cessation. Despite evidence supporting lower morbidity and mortality while adhering to the ABCS, there is a large gap between recommended and implemented treatments. The objectives of this randomized, prospective study are to evaluate current adherence with the ABCS in both the cardiology and primary care clinic, develop and implement an assist model that will shorten the treatment gap, and evaluate the impact of the program on treatment compliance. Fifty patients with coronary artery disease were randomly selected using computer generated ICD9 codes. Baseline adherence to the ABCS was similar to the national average. After implementing the assist model, pharmacotherapy was optimized.

P 1T
5/29

ACCESSION NUMBER: 1999:16509 ADISALERTS
DOCUMENT NUMBER: 800737937
TITLE: Quality of life in the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study
AUTHOR: Hedner E; Halling K
SOURCE: Quality of Life Research (Nov 1, 1998), Vol. 7, pp. 605-606
DOCUMENT TYPE: (Clinical study); Abstract
REFERENCE: Hyperlipidaemia (Index only): Alert no. 4, 1999; PharmacoEconomics (Index only): Alert no. 4, 1999
FILE SEGMENT: Citation
LANGUAGE: English
TI Quality of life in the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study